Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts-Reference-Cited by-同舟云学术

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts

Published:2020-09-09 Issue:1 Volume:23 Page:70-83
ISSN:1536-1632
Container-title:Molecular Imaging and Biology
language:en
Short-container-title:Mol Imaging Biol

Author:

Tran Anh,Koh Tong San,Prawira Aldo,Ho Rebecca Zhi Wen,Le Thi Bich Uyen,Vu Thanh Chung,Hartano Septian,Teo Xing Qi,Chen Way Cherng,Lee Philip,Thng Choon Hua,Huynh Hung^ORCID

Funder

National Research Foundation Singapore

National Medical Research Council

Agency for Science, Technology and Research

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11307-020-01531-7.pdf

Reference39 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Cheng A-L, Kang Y-K, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. https://doi.org/10.1056/NEJMoa0708857

4. Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL (2018) Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med 50:134–139. https://doi.org/10.1038/s12276-018-0159-1

5. El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Hypoxia in Hepatocellular Carcinoma Using Quantitative MRI: Significances, Challenges, and Advances;Journal of Magnetic Resonance Imaging;2023-03-27